8-KItem 5.02 · Officer/Director ChangeItem 9.01 · Financial Statements
IDEXX LABORATORIES INC /DE (IDXX)

IDEXX ($IDXX) filed an 8‑K (Item 9.01) disclosing a Separation Agreement (Exhibit 10.1) between Nimrata…

Filed with the SEC on · Summarized by InvestorsBot

IDEXX ($IDXX) filed an 8‑K (Item 9.01) disclosing a Separation Agreement (Exhibit 10.1) between Nimrata Hunt, PhD and IDEXX dated March 24, 2026. Investors should review the exhibit for material terms. 📄 #8K #CorporateGovernance

The Form 8‑K was signed March 25, 2026 by Sharon E. Underberg (EVP, General Counsel). Exhibit and Inline XBRL cover page included in the filing. 🖊️ $IDXX #SECfiling #Investing

Read the original filing on SEC EDGAR

Get summaries like this in your inbox every morning

Pick up to 20 companies — we read their SEC filings overnight and send you the plain-English version. Free.

Subscribe free

More from IDEXX LABORATORIES INC /DE

IDEXX ($IDXX) and Nimrata Hunt, EVP Global Strategy & Commercial, agreed she’ll cease her role Apr 13,…

8-K · March 26, 2026

IDEXX ($IDXX): Director M.

8-K · February 13, 2026

IDEXX furnished a press release titled “IDEXX Laboratories Announces Fourth Quarter and Full Year 2025…

8-K · February 2, 2026

IDEXX ($IDXX) announced financial results for the quarter and year ended Dec 31, 2025 on Feb 2, 2026.

8-K · February 2, 2026

IDEXX filed Item 9.01 exhibits: a Letter Agreement and an Amended & Restated Change‑in‑Control Agreement…

8-K · January 13, 2026

IDEXX LABORATORIES filed a Form 8‑K (Item 7.01) on Jan 13, 2026 furnishing a press release as Exhibit 99.1…

8-K · January 13, 2026